$120.02 $3.03 (2.6%)

04:00 PM EDT on 08/16/19

Bluebird Bio Inc. (NASDAQ:BLUE)

CAPS Rating: 4 out of 5

Current Price $120.02 Mkt Cap $6.9B
Open $118.09 P/E Ratio 0.00
Prev. Close $116.99 Div. (Yield) $0.00 (0.0%)
Daily Range $117.96 - $120.34 Volume 282,310
52-Wk Range $95.67 - $163.43 Avg. Daily Vol. 12

Caps

How do you think NASDAQ:BLUE will perform against the market?

Add Stock to CAPS Watchlist

All Players

268 Outperform
17 Underperform
 

All-Star Players

91 Outperform
6 Underperform
 

Wall Street

6 Outperform
0 Underperform
 

Top NASDAQ:BLUE Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

SaintCroix (99.05)
Submitted February 14, 2018

I am very impressed with Nick Leschly. You can watch his Ted Talk here:https://www.youtube.com/watch?v=Ez560GnkSrE

TMFFlygal (99.52)
Submitted December 08, 2015

Selling for a while after the huge drop today, good for a trade

NASDAQ:BLUE VS S&P 500 (SPY)

Fools bullish on NASDAQ:BLUE are also bullish on:

Fools bearish on NASDAQ:BLUE are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about BLUE.

Recs

0
Member Avatar SurfingCabarete (52.62) Submitted: 7/9/2019 12:18:18 PM : Outperform Start Price: $131.71 NASDAQ:BLUE Score: -6.17

another bet on gene editing

Recs

0
Member Avatar jbonefish (59.73) Submitted: 6/14/2019 10:51:02 PM : Outperform Start Price: $118.05 NASDAQ:BLUE Score: +1.93

In the “age of miracles” Bluebird is out in front in applying the science and focused on the types of diseases (single gene mutations) that are most likely to result in breakthrough treatments initially. Rather than being a good moonshot story, BLUE is doing the work that will solve problems for patients - that is a better recipe for long term financial success than a good story.

Recs

0
Member Avatar MarkFitzFool (42.05) Submitted: 5/11/2019 12:39:01 PM : Outperform Start Price: $132.45 NASDAQ:BLUE Score: -11.63

$BLUE is a leader in the new wave, the future, of personalized genomic therapies based on both gene editing and immunotherapy. They're ahead of Edits when it comes to bringing their Beta-Thalassemia and Sickle Cell Disease therapies to market. Mark my words, they will be the first to market with those therapies (although there is room for several players in the space). They have impressive partnerships with Regeneron, Celgene, Boston Children's Hospital, Seattle Children's Hospital, etc. I know from speaking to some senior scientists at the company, that they plan to file FDA approval for at least four candidate therapies within the next two years. Beta-Thalassemia approval in the EU will likely come first. Is it a risky investment? Yes, a bit, as is the nature of virtually all developmental and pre-clinical stage biotechs, but they are a true leader, and I don't see them going away or failing anytime soon.

Leaderboard

Find the members with the highest scoring picks in BLUE.

Score Leader

DoubleBagel

DoubleBagel (33.58) Score: +669.10

The Score Leader is the player with the highest score across all their picks in BLUE.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
portefeuille12 29.92 4/16/2014 Outperform 5Y $19.11 +528.05% +55.49% +472.56 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. efarev 98.53 11/5/2013 Outperform 5Y $20.53 +484.61% +64.04% +420.57 0 Comment
portefeuille2 98.68 4/11/2014 Outperform 5Y $20.74 +478.69% +58.74% +419.95 0 Comment
portefeuille3 96.88 4/11/2014 Outperform 5Y $20.74 +478.69% +58.87% +419.82 0 Comment
portefeuille6 99.58 4/11/2014 Outperform 5Y $20.91 +473.98% +59.08% +414.90 0 Comment
johninmadison 85.05 4/7/2014 Outperform 5Y $21.07 +469.63% +55.33% +414.30 0 Comment
HoosierDoozer < 20 2/5/2014 Outperform 5Y $20.84 +475.91% +65.20% +410.71 0 Comment
portefeuille 98.23 4/8/2014 Outperform 5Y $21.44 +459.79% +56.64% +403.15 1 Comment
jack0071 71.53 1/8/2014 Outperform 5Y $21.47 +459.01% +57.40% +401.61 0 Comment
jtothes 75.39 2/14/2014 Outperform 3Y $21.88 +448.54% +57.92% +390.61 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackEvercorePar 84.14 6/19/2018 Outperform NS $179.40 -33.10% +5.38% -38.48 0 Comment
TrackBMOCapital < 20 6/6/2017 Outperform NS $95.43 +25.77% +18.66% +7.11 0 Comment
Anonymous331 34.53 5/30/2017 Outperform 5Y $78.60 +39.82% +0.31% +39.51 6/16/2017 @ $109.90 0 Comment
TrackJimCramer 86.43 5/27/2015 Outperform 3W $189.69 -36.73% +35.75% -72.48 0 Comment
TrackJimCramer 86.43 3/13/2015 Underperform 3W $119.93 +58.17% +3.34% -54.83 5/27/2015 @ $189.69 0 Comment
TrackPiperJaff 84.76 12/9/2014 Outperform NS $77.42 +55.02% +41.29% +13.74 0 Comment
TrackRothCapital 61.09 9/22/2014 Outperform NS $36.70 +227.03% +44.12% +182.91 0 Comment
TrackJimCramer 86.43 3/20/2014 Outperform 3W $26.83 +347.00% +9.63% +337.37 3/13/2015 @ $119.93 0 Comment
TrackWedbush 88.42 7/15/2013 Outperform NS $32.37 +270.78% +71.91% +198.87 0 Comment